Johnson & Johnson
$762M 13F equity value
15 Holdings
Quarter ended September 30, 2026
The latest 13F on file for Johnson & Johnson covers the quarter ended September 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INC | 2,449,183 | $345M | 45.3% |
| NBTX | NANOBIOTIX | 5,623,816 | $175M | 23.0% |
| MGTX | MEIRAGTX HLDGS PLC | 6,641,064 | $73M | 9.6% |
| RAPP | RAPPORT THERAPEUTICS INC | 1,784,517 | $60M | 7.9% |
| CTNM | CONTINEUM THERAPEUTICS INC | 1,979,173 | $27M | 3.5% |
| CBRS | CEREBRAS SYSTEMS INC | 128,649 | $23M | 3.0% |
| XNCR | XENCOR INC | 748,062 | $19M | 2.5% |
| LEGN | LEGEND BIOTECH CORP | 814,586 | $16M | 2.1% |
| FATE | FATE THERAPEUTICS INC | 3,379,064 | $8M | 1.1% |
| CVRX | CVRX INC | 4,024,861 | $7M | 0.9% |
Track Johnson & Johnson's 13F portfolio: $762M in reported holdings, 15 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}